

Contents

1	Introduction	1
1.1	Protein–Protein Interactions and Their Small-Molecule Modulators	1
1.1.1	Characteristics of Protein–Protein Interactions	1
1.1.2	Intervention of Protein–Protein Interactions Using Small Molecules	3
1.1.2.1	Leukocyte Function-Associated Antigen-1	5
1.1.2.2	Inhibitor of Apoptosis Proteins	6
1.1.2.3	Bromodomains	6
1.1.2.4	Human Immunodeficiency Virus Integrase	6
1.1.2.5	B-Cell Lymphoma-2 Family/B-Cell Lymphoma-2 Homology 3 Proteins Interaction	7
1.1.2.6	Mouse Double Minute 2–p53 Interaction	7
1.2	Features of Peptide as Molecular Tools	8
1.2.1	Advantages of Peptides as Molecular Tools	8
1.2.2	Disadvantages of Peptides as Molecular Tools	11
1.3	Helical Structures and Their Characterization	12
1.3.1	Different Types of Helices	12
1.3.1.1	α -Helix	12
1.3.1.2	3_{10} -Helix	12
1.3.1.3	π -Helix	13
1.3.2	Characterization of Helical Peptides	15
1.3.2.1	Circular Dichroism	15
1.3.2.2	X-ray Crystallography	16
1.3.2.3	Nuclear Magnetic Resonance (NMR)	17
1.4	Stabilization of Peptides	18
1.4.1	Peptide Stabilization via Cyclization	18
1.4.1.1	Monocyclization	18
1.4.1.2	Multicyclization	19
1.4.2	Peptide Stabilization via Backbone Reconstruction	21
1.4.2.1	Methylation	21
1.4.2.2	Foldamers	23
	References	27

2	Construction of Constrained Helices	35
2.1	Side-Chain Cross-linking	35
2.1.1	Disulfide Bond	35
2.1.2	Amide and Ester	37
2.1.3	All-Hydrocarbon Stapled Peptide	42
2.1.4	Thioether	48
2.1.5	Azole	56
2.2	End Nucleation	57
2.2.1	Macrocyclic-Based N-cap Templates	58
2.2.2	Hydrogen Bond Surrogate Approaches	60
2.2.3	N-Terminal Side Chain Constrains as Helix-Nucleating Templates	61
	References	62
3	Properties of Stabilized Peptides	69
3.1	Helicity	69
3.1.1	Ring Size	69
3.1.2	Rigidity	74
3.1.3	Comparison	79
3.2	Binding Affinity	80
3.2.1	Helicity	80
3.2.2	Cyclization Position	81
3.2.3	Substitution	84
3.3	Cell Permeability	84
3.3.1	Amphiphilicity: Hydrophobicity and Isoelectric Point	84
3.3.2	Helicity	87
3.3.3	Summary	89
3.4	Nonspecific Toxicity	89
3.5	Stability	91
3.5.1	Proteolytic Stability	91
3.5.2	Pharmacokinetic Properties	95
3.6	Additional Features	98
	References	103
4	Applications of Constrained Helices	107
4.1	Cancer	107
4.1.1	MDM2/X	107
4.1.2	B-Cell Lymphoma 2 (MCL-1/BCL-2/BCL-XL)-BID/Noxa/BAX/BIM/PUMA	110
4.1.3	NOTCH	114
4.1.4	Insulin Receptor Substrate 1	118
4.1.5	Ras	120
4.1.6	Rab	124
4.1.7	β -Catenin BCL-9/AXIN	126
4.1.8	Epidermal Growth Factor Receptor	130

4.1.9	Estrogen Receptor α	135
4.1.10	Hypoxia-Inducible Factor	138
4.1.11	Embryonic Ectoderm Development – Enhancer of Zeste Homolog 2	140
4.2	Infectious Disease	143
4.2.1	HIV	143
4.2.2	Respiratory Syncytial Virus F (RSV)	148
4.3	Metabolic Disease	150
4.3.1	Glucokinase-Phospho-BAD	150
	References	152
5	Stabilized Peptide Covalent Inhibitors	159
5.1	Methodologies of Peptide Covalent Inhibitor	159
5.1.1	Covalent Warhead	160
5.1.2	Stapling Method	162
5.2	Applications	162
5.2.1	BCL-2 Family Proteins As Target	163
5.2.2	MDM2 and MDM4 As Target	164
5.2.3	Sulfonium Tethered Peptide	168
5.2.4	Others	176
	References	177
6	Stabilized Peptide PROTAC	181
6.1	Proteolysis-Targeting Chimera (PROTAC)	181
6.2	Design of Peptide PROTAC	181
6.2.1	Exploitation of E3 Ubiquitin Ligase-Recruiting Ligand	182
6.2.2	Design of Stabilized Peptide Ligand	183
6.2.3	Impact of Linker	184
6.3	Therapeutic Applications of Stabilized Peptide PROTAC	184
6.3.1	Targeting ER α	185
6.3.2	Targeting β -Catenin	188
	References	188
7	Stabilized Peptide for Drug Delivery	191
7.1	Cell-Penetrating Peptides (CPPs)	191
7.1.1	Classification of CPPs	192
7.1.2	Mechanism of Cell Penetration of CPPs	193
7.1.3	Applications of CPPs	194
7.2	Cell-Permeable Cyclic Peptides (Cyclic CPPs)	196
7.2.1	Cyclic CPPs-Mediated Drug Delivery	198
7.2.2	Cyclo-RGD	202
7.3	Co-assembly Nanocarrier System	204
7.4	Examples of Stabilized Peptide Drugs	206
	References	208

8	Outlook	213
8.1	The Development of Peptide-Stabilizing Methods	213
8.2	Applications of Stabilized Helical Peptides	218
	References	220
	Index	223